Background
Methods
Patients and tissue samples
Cell culture, transfection, and treatment
siRNA | mRNA target |
---|---|
Scr | ATAGTTCGTCCACTTCAGC |
NEK2 .1 | CGGAGGAAGAGTGATGGCAAGATAT |
NEK2 .2 | GAAGTGATGGTGGTCATACCGTATT |
NEK2 .3 | GCTGTATGAGTTATGTGCATTAATG |
Quantitative real-time RT-PCR
Western blotting analysis
Tumor growth
Immunohistochemistry analysis
Statistical analysis
Results
Depleting NEK2 expression reduces cell proliferation in PCa cells
Depletion of NEK2 expression suppresses tumorigenicity of LNCaP cells
The expression level of NEK2 is associated with the clinicopathological characteristics of PCa and tumor recurrence time of PCa patients
Clinical feature | IRS of NEK2 in our cohort | NEK2 expression in Taylor dataset | ||||
---|---|---|---|---|---|---|
Case |
\( \overline{X}\pm s \)
|
p
| Case |
\( \overline{X}\pm s \)
|
p
| |
Age(years) | ||||||
<71 years | 85 | 3.67 ± 1.43 | 0.904 | 146 | 7.54 ± 0.29 | 0.717 |
≥71 years | 95 | 3.64 ± 1.70 | 4 | 7.48 ± 0.26 | ||
Serum PSA | ||||||
<4 (ng/ml) | - | - | - | 24 | 7.58 ± 0.32 | 0.440 |
≥4 (ng/ml) | - | - | 123 | 7.53 ± 0.29 | ||
Gleason score | ||||||
<8 | 70 | 3.81 ± 1.08 | <0.001 | 117 | 7.48 ± 0.25 | 0.011 |
≥8 | 28 | 5.36 ± 1.39 | 22 | 7.71 ± 0.37 | ||
Pathological Stage | ||||||
T2 | 70 | 3.81 ± 1.08 | <0.001 | 86 | 7.48 ± 0.23 | 0.063 |
T3 | 29 | 5.31 ± 1.39 | 55 | 7.58 ± 0.35 | ||
Metastasis | ||||||
No | 99 | 4.25 ± 1.35 | - | 122 | 7.47 ± 0.25 | <0.001 |
Yes | 0 | - | 28 | 7.81 ± 0.33 | ||
Overall survival | ||||||
Alive | - | - | - | 131 | 7.51 ± 0.27 | 0.086 |
Die | - | - | 19 | 7.68 ± 0.38 | ||
PSA failure | ||||||
Negative | - | - | - | 104 | 7.46 ± 0.25 | <0.001 |
Positive | - | - | 36 | 7.66 ± 0.31 |